New adMare white paper maps capital flows in Canadian life sciences, urges policy shift

Over the past decade, Canadian life science companies raised just 2 percent of the amount raised by U.S. life science companies. adMareBioInnovations’ latest white paper, “Does Canada Own its Life Sciences Future?” offers a compelling and timely analysis of capital flows shaping Canada’s life sciences sector and outlines strategic steps to build a stronger, sustainable life sciences ecosystem in Canada.

The report finds that over 75 percent of the investors benefiting from Canada’s top 20 life sciences exits are international leading to significant outflows of intellectual property and economic value. The report emphasizes on the remarkable growth of Canadian therapeutics, highlights the critical gaps in domestic investment, and reinforces the critical need to strengthen Canada’s life sciences venture capital ecosystem, particularly through greater participation from domestic institutional investors such as pension funds.

Congratulations to our valued partner, adMare, on the publication of this important white paper!